The potential of sestrins as therapeutic targets for diabetes
dc.contributor.author | Dong, X. Charlie | |
dc.contributor.department | Department of Biochemistry & Molecular Biology, IU School of Medicine | en_US |
dc.date.accessioned | 2017-06-08T14:00:30Z | |
dc.date.available | 2017-06-08T14:00:30Z | |
dc.date.issued | 2015-08 | |
dc.description.abstract | Sestrins (Sesn1/2/3) belong to a small protein family that has versatile biological functions. In addition to initially characterized oxidoreductase activity, sestrins also have oxidoreductase-independent functions, including activation of AMP-activated protein kinase, inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) and activation of mTORC2. As these kinases are important for metabolic regulation, sestrins have a favorable profile as potential therapeutic targets for metabolic diseases such as diabetes. Recent data are in line with such a notion. In this editorial, I have attempted to provide a brief update on the major findings in regard to sestrins in metabolism. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Dong, X. C. (2015). The Potential of Sestrins as Therapeutic Targets for Diabetes. Expert Opinion on Therapeutic Targets, 19(8), 1011–1015. http://doi.org/10.1517/14728222.2015.1044976 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/12911 | |
dc.language.iso | en_US | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.relation.isversionof | 10.1517/14728222.2015.1044976 | en_US |
dc.relation.journal | Expert Opinion on Therapeutic Targets | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.source | PMC | en_US |
dc.subject | Mechanistic target of rapamycin complex 1 | en_US |
dc.subject | Mechanistic target of rapamycin complex 2 | en_US |
dc.subject | Sestrin | en_US |
dc.subject | V-akt murine thymoma viral oncogene homolog | en_US |
dc.title | The potential of sestrins as therapeutic targets for diabetes | en_US |
dc.type | Article | en_US |